29 related articles for article (PubMed ID: 38460433)
1. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
Greenberg PL; Lee SJ; Advani R; Tallman MS; Sikic BI; Letendre L; Dugan K; Lum B; Chin DL; Dewald G; Paietta E; Bennett JM; Rowe JM
J Clin Oncol; 2004 Mar; 22(6):1078-86. PubMed ID: 15020609
[TBL] [Abstract][Full Text] [Related]
2. A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.
Advani AS; Cooper B; Visconte V; Elson P; Chan R; Carew J; Wei W; Mukherjee S; Gerds A; Carraway H; Nazha A; Hamilton B; Sobecks R; Caimi P; Tomlinson B; Malek E; Little J; Miron A; Pink J; Maciejewski J; Unger A; Kalaycio M; de Lima M; Sekeres MA
Clin Cancer Res; 2019 Jul; 25(14):4231-4237. PubMed ID: 30992301
[TBL] [Abstract][Full Text] [Related]
3. Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia.
Atchley E; Weis TM; Derkach A; Galera PK; Xiao W; Glass J; DeWolf S; Roshal M; Shah R; Stump SE
Leuk Res; 2023 Jul; 130():107311. PubMed ID: 37182399
[TBL] [Abstract][Full Text] [Related]
4. Novel homobarringtonie-containing therapy for the treatment of patients with primary acute myeloid leukemia that are resistant to conventional therapy.
He J; Li L; Zhu J; Zheng W; Wu W; Zheng Y; Ye X
Oncol Lett; 2017 Dec; 14(6):7597-7607. PubMed ID: 29344207
[TBL] [Abstract][Full Text] [Related]
5. A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience.
Karasek M; Armatys A; Skarupski M; Bołkun Ł; Budziszewska K; Drozd-Sokołowska J; Zarzycka E; Mensah-Glanowska P; Gajewska M; Hałka J; Kopacz A; Prejzer W; Chyrko O; Wróbel T; Wierzbowska A; Sobas M
Front Oncol; 2024; 14():1395992. PubMed ID: 38835383
[TBL] [Abstract][Full Text] [Related]
6. Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data.
Abé C; Keto J; Lilja M; Konradsen M; Mesterton J; Höglund M; Lazarevic V; Lehmann S; Juliusson G
Leuk Lymphoma; 2024 Jun; ():1-9. PubMed ID: 38861379
[TBL] [Abstract][Full Text] [Related]
7. Acute Myeloid Leukemia Presenting as Common Colds: An Uncommon Consideration.
Fusillo TF; Millman S; Menghrajani K
Cureus; 2024 Jan; 16(1):e53217. PubMed ID: 38425594
[TBL] [Abstract][Full Text] [Related]
8. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
9. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Montesinos P
Ann Hematol; 2018 Jul; 97(7):1115-1153. PubMed ID: 29680875
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia.
Zhong S; Kurish H; Walchack R; Li H; Edwards J; Singh A; Advani A
Leuk Res; 2024 Apr; 139():107468. PubMed ID: 38460433
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
12. [Mitoxantrone, etoposide, and cytarabine combination therapy for acute myeloid leukemia patients failing to achieve a complete remission after induction chemotherapy: a single-center experience].
Morita-Fujita M; Yabushita T; Shimomura Y; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Ishikawa T
Rinsho Ketsueki; 2018; 59(7):858-864. PubMed ID: 30078794
[TBL] [Abstract][Full Text] [Related]
13. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.
Gill H; Yim R; Pang HH; Lee P; Chan TSY; Hwang YY; Leung GMK; Ip HW; Leung RYY; Yip SF; Kho B; Lee HKK; Mak V; Chan CC; Lau JSM; Lau CK; Lin SY; Wong RSM; Li W; Ma ESK; Li J; Panagiotou G; Sim JPY; Lie AKW; Kwong YL
Cancer Med; 2020 May; 9(10):3371-3382. PubMed ID: 32187883
[TBL] [Abstract][Full Text] [Related]
14. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
Christian S; Arain S; Patel P; Khan I; Calip GS; Agrawal V; Sweiss K; Griffin S; Cahill K; Konig H; Esen A; Shergill A; Odenike O; Stock W; Quigley JG
Am J Hematol; 2020 Aug; 95(8):937-943. PubMed ID: 32311140
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
